02-05 November 2023 Marseille
![]() |
![]() |
![]() |
![]() |
P-001 | Programmed death-ligand (PD-L1) immunoexpression and clinical outcomes in Penile Squamous Cell Carcinoma | Ines Peyroteo | ![]() |
![]() |
|||
O-001 | MRI in penile cancer: Correlating examination and histopathology with imaging | Mayank Gupta | ![]() |
![]() |
|||
P-2 | Saving More Than Just Skin: A Study of Penile Sparing Approaches in Cancer Treatment | George Shaker | ![]() |
![]() |
|||
P-005 | The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer | Maarten Donswijk | ![]() |
![]() |
|||
O-008 | Intense surveillance for patients treated with radical prostatectomy and adverse pathologic features: early results from easy-1 (early salvage radiotherapy-1) protocol | Martina Monti | ![]() |
![]() |
|||
P-009 | The probability of metastases within different Prostate-Specific Antigen (PSA) ranges using Prostate-Specific Membrane Antigen (PSMA) positron emission tomography in patients with newly diagnosed prostate cancer | Wietske Luining | ![]() |
![]() |
|||
O-010 | The 3 year follow-up of the CRIMI study | Marinka Remmelink | ![]() |
![]() |
|||
O-011 | Post-chemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer at a national referral center | Panagiotis Vlachostergios | ![]() |
![]() |
|||
O-12 | Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial | Laura Hendrickson | ![]() |
![]() |
|||
P-012 | Telomere biology as a prognostic factor in radical prostatectomy | Juan Manuel Rubio Galisteo | ![]() |
![]() |
|||
P-017 | MRI/US fusion, transperineal prostate biopsy utilising electro-magnetic Vector needle tracking, under local anesthesia | Marta De Santis | ![]() |
![]() |
|||
P-021 | The value of PSMA-PET in Addition to mpMRI and Systematic Biopsies to Select Patients for Hemi-ablative Focal Therapy in Prostate Cancer | Matthijs Scheltema | ![]() |
![]() |
|||
P-024 | A randomized Phase 3 trial of Metformin in patients initiating androgen deprivation therapy as PRevention and Intervention of MEtabolic syndrome: The PRIME Study | Nawaid Usmani | ![]() |
![]() |
|||
P-032 | Stereotactic prostate radiotherapy with or without androgen deprivation therapy: A phase III, multi-institutional randomized-controlled trial. The SPA trial | Vittorio Morelli | ![]() |
![]() |
|||
P-035 | Validation of diagnostic nomograms based on mass spectrometry-based urinary biomarkers to distinguish clinically significant prostate cancer: complementing MRI pathway | Ana Cristina Morillo Tejedor | ![]() |
![]() |
|||
P-038 | Local anaesthesia transperineal (LATP) biopsy of the prostate: a new era for prostate cancer diagnosis? | Paul Lim | ![]() |
![]() |
|||
P-039 | Using PSMA PET to Guide Prostate Biopsies and Stage Men at High-Risk of Prostate Cancer | Yves Bodar | ![]() |
![]() |
|||
P-046 | Salvage cryotherapy for prostate cancer | Duarte Brito | ![]() |
![]() |
|||
P-049 | 10-year experience of whole gland cryoablation: analysis of biochemical recurrence | Alejandro Reviriego Barrús | ![]() |
![]() |
|||
P-054 | Toxicity results of a multicentre randomized phase 3, non-inferiority trial on moderate hypofractionated radiotherapy. | Valerie Fonteyne | ![]() |
![]() |
|||
P-060 | Minimizing neurovascular bundle dose while maintaining target coverage in prostate radiotherapy | Victor Brand | ![]() |
![]() |
|||
P-064 | Real-World Treatment and Outcomes in Localized Prostate Cancer | Jose M. Calderon | ![]() |
![]() |
|||
P-065 | PSMA PET/CT in Biochemically Recurrent Prostate Cancer: multicenter external validation of a risk prediction nomogram | Laura Chamorro Castillo | ![]() |
![]() |
|||
P-068 | Serum levels of vitamin E (Vit E) in patients with proctitis after radical radiotherapy for localized prostate cancer | Geovana Marques Guimaraes | ![]() |
![]() |
|||
P-069 | PSA persistence after prostatectomy prognosis and the effect of adjuvant radiotherapy | Axel Möller | ![]() |
![]() |
|||
P-071 | The association between patient- and disease characteristics, and the risk of disease progression in patients with prostate cancer on active surveillance | Matthijs Duijn | ![]() |
![]() |
|||
P-077 | Baseline health-related quality of life as a prognostic indicator for survival in men with intermediate risk prostate cancer following radical prostatectomy | Thilo Westhofen | ![]() |
![]() |
|||
P-081 | Real World Utilisation of Androgen Deprivation Therapy Among Urology Practices: Characterising Initiation and Transition to Relugolix for Patients with Prostate Cancer (The REAL ADT Transitions Study) | Thierry Schulmann | ![]() |
![]() |
|||
P-083 | Post-metastasis survival in high-risk localised and locally advanced prostate cancer patients undergoing primary treatment in the United States: A retrospective study | Erin OBrien | ![]() |
![]() |
|||
P-085 | The optimal timing of ARAT administration against nmCRPC | Kazuhiro Matsumoto | ![]() |
![]() |
|||
P-087 | Acute toxicity results from a multicenter randomized phase 3 trial comparing external beam radiotherapy alone with external beam radiotherapy combined with brachytherapy in intermediate/high risk prostate cancer patients | Miranda Christianen | ![]() |
![]() |
|||
P-088 | Salvage radiotherapy after prostatectomy; trends and variation in Dutch clinical practice | Floor Staal | ![]() |
![]() |
|||
P-093 | Mutational profile of hormone-sensitive and castration-resistant metastatic prostate cancer | Clara Velasco Balanza | ![]() |
![]() |
|||
P-096 | Real-world data analysis of clinical characteristics in metastatic hormone-sensitive prostate cancer: Are patients from RCTs the same from real life? Data from the European network of excellence for big data in prostate cancer (PIONEER). | Juan Gomez Rivas | ![]() |
![]() |
|||
P-098 | Real-world characterization of disease management and progression in metastatic and nonmetastatic castrate-resistant prostate cancer patients in Portugal: CaPA study | Catarina Leitao | ![]() |
![]() |
|||
P-100 | Apalutamide in Metastatic Prostate Cancer real life experience | Duarte Brito | ![]() |
![]() |
|||
P-101 | Treatment (tx) patterns and outcomes in the real world (rw) among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in Europe | Melissa Kirker | ![]() |
![]() |
|||
P-102 | Matching-Adjusted Indirect Comparisons (MAICs) of Talazoparib versus Olaparib and Niraparib for First-line (1L) Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Melissa Kirker | ![]() |
![]() |
|||
P-104 | Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: Freedom from biochemical, radiological progression free survival and freedom from following treatment approaches within a randomized phase II trial (ARTO NCT03449719) | Giulio Francolini | ![]() |
![]() |
|||
P-105 | Is achieving undetectable PSA (uPSA) a prognostic factor for improved overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving intensified treatments? | Jose M. Calderon | ![]() |
![]() |
|||
P-106 | The conundrum of treating metastatic hormone sensitive prostate cancer | Tessa van Elst | ![]() |
![]() |
|||
P-107 | A network meta-analysis on the safety of systemic treatments in metastatic hormone-sensitive prostate cancer patients | Irene Luccarini | ![]() |
![]() |
|||
P-108 | Expert consensus recommendations for managing adverse events in patients with metastatic prostate cancer treated with poly(ADP-ribose) polymerase inhibitor (PARPi) novel hormonal therapy (NHT) combination therapy | Hannah Dalglish | ![]() |
![]() |
|||
P-109 | An evaluation of service diversification in response to increasing therapeutic indications for 2nd generation hormone therapy in prostate cancer | Alicia Hague | ![]() |
![]() |
|||
P-111 | New or worsening type 2 diabetes mellitus (T2DM) in men treated with enzalutamide (ENZ) or abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC): EVADE study | Anna George | ![]() |
![]() |
|||
P-112 | Analysis of prostate-specific antigen (PSA) kinetics in the third month of treatment with apalutamide in metastatic castration-sensitive prostate cancer (mCSPC) | Juan Luis Sanz Miguelañez | ![]() |
![]() |
|||
P-114 | The multicenter and randomized PROSFIT trial: Smart wearables to evaluate the impact of lifestyle changes in patients with metastatic hormone sensitive prostate cancer (mHSPC) | Teresa Alonso Gordoa | ![]() |
![]() |
|||
P-116 | Characteristics and healthcare resource utilisation (HRU) of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on enzalutamide (ENZ) or abiraterone acetate (AA) in England: PROCCO study | Anna George | ![]() |
![]() |
|||
P-117 | Retrospective Study to Describe Characteristics and Treatment Patterns of Patients with Metastatic Castration-resistant Prostates Cancer | Sahin Bahadir | ![]() |
![]() |
|||
P-118 | Real-world European study of treatment (tx) patterns in men with metastatic castration-resistant prostate cancer (mCRPC) | Melissa Kirker | ![]() |
![]() |
|||
P-128 | The influence of the prostate radiotherapy dose in the prediction of complete response in synchronous oligometastatic prostate cancer patients | Milo Gruji&263; | ![]() |
![]() |
|||
P-129 | Real-world data analysis of treatment outcomes for patients with metastatic hormone-sensitive prostate cancer: development of a survival prediction model. Results from the European network of excellence for big data in prostate cancer (PIONEER) | Juan Gomez Rivas | ![]() |
![]() |
|||
P-132 | Reliability and efficiency of the CAPRI-3 metastatic prostate cancer registry powered by artificial intelligence | Dianne Bosch | ![]() |
![]() |
|||
P-133 | Second line PSMA-targeted salvage treatment in patients with mi N1/M1a-b oligorecurrent PCa | Martina Monti | ![]() |
![]() |
|||
P-135 | Homologous recombination repair mutation (HRRm) testing patterns among men with metastatic castration-resistant prostate cancer (mCRPC): Results from a real-world (rw) study in Europe | Melissa Kirker | ![]() |
![]() |
|||
P-139 | Real-world (rw) homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in five European countries | Melissa Kirker | ![]() |
![]() |
|||
P-140 | Patient-reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) enzalutamide (ENZA) vs placebo (PBO) ENZA: Results from a phase 3 (TALAPRO-2) study | Saif Shaman | ![]() |
![]() |
|||
P-144 | COmplete ReSponse After systemic Immunotherapy /- Resection of residual disease in advanced ccRCC : the CORSAIR study | Philippe Boudier | ![]() |
![]() |
|||
P-155 | Factors affecting acute kidney injury and subsequent renal function recovery after robot-assisted partial nephrectomy for clinical T1a renal masses | Toshikazu Takeda | ![]() |
![]() |
|||
P-156 | Zanzalintinib (XL092) and nivolumab in nonclear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study (NCT05678673) | Kim Nguyen | ![]() |
![]() |
|||
P-160 | Clinical characterisation, prognosis and assessment of predictive score for response to treatment of metastatic renal cells carcinoma with rhabdoid component | Louis Vallois | ![]() |
![]() |
|||
P-166 | Real-world outcomes of cabozantinib treatment after first-line checkpoint inhibitor-based combination therapy for patients with advanced renal cell carcinoma: CARINA study results | Lauren Reed | ![]() |
![]() |
|||
P-168 | Nivolumab as a treatment for metastatic renal cancer in second and successive lines. Experience at our hospital. | María Luisa Garrido Onecha | ![]() |
![]() |
|||
P-172 | Perioperative and long-term oncological outcomes after local tumor ablation for complex (PADUA Score =10) cT1a renal tumors: a multicenter analysis | Martina Monti | ![]() |
![]() |
|||
P-174 | The efficacy and safety of cone beam computed tomography for percutaneous renal cell carcinoma cryoablation: A single-center long-term follow-up study | Matthijs Duijn | ![]() |
![]() |
|||
P-178 | Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential ion for adjuvant therapy | Panagiotis Vlachostergios | ![]() |
![]() |
|||
P-181 | Proposal and internal validation of a nomogram for the prediction of local recurrence-free survival after percutaneous ablation for ct1 renal masses | Sara Tamburini | ![]() |
![]() |
|||
P-184 | Monitoring of pulmonary function by diffusing capacity of lung for carbon monoxide(DLCO) during BEP therapy for testicular cancer | Takeshi Kishida | ![]() |
![]() |
|||
P-186 | Overall Response rate with baby-BOP induction chemotherapy in patients with poor-risk, metastatic germ-cell tumors patients: A Retrospective Study in a Mexican hospital. | Miriam Alejandra Nájar Rodríguez | ![]() |
![]() |
|||
P-211 | Endoscopic ablation of UTUC in solitary kidney patients | Evangelia Papadimitriou | ![]() |
![]() |
|||
P-212 | Oncological outcomes of chemohyperthermia with HIVEC for BCG-unresponsive non-muscle invasive bladder cancer : results from a multicenter national database | Géraldine Pignot | ![]() |
![]() |
|||
P-214 | C-reactive protein is a prognostic factor after pembrolizumab for metastatic upper urothelial carcinoma | Hirotaka Nagasaka | ![]() |
![]() |
|||
P-216 | Neutrophil-to-eosinophil ratio (NER) predicts the efficacy of avelumab in patients with advanced Urothelial Carcinoma (aUC) enrolled in the MALVA study (Meet-URO 25) | ELISABETTA GAMBALE | ![]() |
![]() |
|||
P-219 | Evaluation of the use of postoperative single-shot instillation chemotherapy after TURBT and reasons for not administering it | Michal Fedorko | ![]() |
![]() |
|||
P-224 | Pembrolizumab Versus Atezolizumab in The Treatment of Advanced Urothelial Cancer: A Single Institution Experience | Nafie Makady | ![]() |
![]() |
|||
P-225 | A real word study of avelumab first-line maintenance in advanced urothelial carcinoma | Helena Guedes | ![]() |
![]() |
|||
P-226 | Delay of radical cystectomy in patients treated with neoadjuvant chemotherapy is associated with worse oncological outcomes | Sieb Nuijens | ![]() |
![]() |
|||
P-228 | Neoadjuvant versus adjuvant chemotherapy in muscle-invasive bladder cancer: The RealBLADDER study. Results on behalf of the GOIRC | ELISABETTA GAMBALE | ![]() |
![]() |
|||
P-241 | Atezolizumab as treatment of urothelial carcinoma in second line of metastatic disease. Experience in our institution. | Laura Lopez | ![]() |
![]() |
|||
P-244 | COVID-19 pandemic and non-muscle-invasive bladder cancer: impact on follow-up and disease recurrence | Frederico Portugal Gaspar | ![]() |
![]() |
|||
P-251 | Inhibitory coreceptors in variant histologies of bladder cancer the next chapter in urooncology? | Severin Rodler | ![]() |
![]() |
|||
P-254 | Prognostic factors for urachal carcinoma | Atsuto Suzuki | ![]() |
![]() |
|||
P-256 | Prognostic relevance of Platelet-to-Lymphocyte Ratio in patients with Muscle-Invasive Bladder Cancer Patients: real world data from a retrospective multicenter analysis | Giovanna Pecoraro | ![]() |
![]() |
|||
P-264 | The prognostic value of pre-neoadjuvant chemotherapy prognostic nutritional index, systemic inflammatory response index and neutrophil-to-lymphocyte ratio in muscle invasive bladder cancer | Maria Joao Ramos | ![]() |
![]() |
|||
P-266 | Gender Influence on Efficacy and Immune-Related Adverse Events of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer Patients | Can Aydogdu | ![]() |
![]() |
|||
P-268 | Health-related Quality of Life Outcomes in patients with Muscle Invasive Bladder Cancer after treatment: Results of a Large, Population-based, Prospective Cohort | Siberyn Nuijens | ![]() |
![]() |
02-05 November 2023 Marseille
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|